Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.

Autor: Fredrickson J; Clinical Imaging Group, Genentech, Inc., South San Francisco, California, USA.; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA., Serkova NJ; Department of Anesthesiology, University of Colorado Cancer Center, Aurora, Colorado, USA., Wyatt SK; Department of Biomedical Imaging, Genentech, Inc., South San Francisco, California, USA., Carano RA; Department of Biomedical Imaging, Genentech, Inc., South San Francisco, California, USA., Pirzkall A; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA., Rhee I; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA., Rosen LS; Department of Medicine, Division of Hematology and Oncology, UCLA, Santa Monica, California, USA., Bessudo A; San Diego Pacific Oncology Hematology Associates Inc., Encinitas, California, USA., Weekes C; Department of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA., de Crespigny A; Clinical Imaging Group, Genentech, Inc., South San Francisco, California, USA.; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA.
Jazyk: angličtina
Zdroj: Magnetic resonance in medicine [Magn Reson Med] 2017 Feb; Vol. 77 (2), pp. 814-825. Date of Electronic Publication: 2016 Feb 26.
DOI: 10.1002/mrm.26167
Abstrakt: Purpose: To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase I trial of a novel therapy in patients with advanced metastatic disease.
Methods: Scans were acquired before, immediately after, and 48 h after injection, at screening and after 2 weeks of treatment. ΔR 2 , ΔR2*, vessel density (Q), and relative vascular volume fractions (VVF) were estimated in both normal tissue and tumor, and compared with model-derived theoretical and experimental estimates based on preclinical murine xenograft data.
Results: R 2 and R2* relaxation rates were still significantly elevated in tumors and liver 48 h after ferumoxytol injection; liver values returned to baseline by week 2. Q was relatively insensitive to changes in ΔR2*, indicating lack of dependence on contrast agent concentration. Variability in Q was higher among human tumors compared with xenografts and was mostly driven by ΔR 2 . Relative VVFs were higher in human tumors compared with xenografts, while values in muscle were similar between species.
Conclusion: Clinical ferumoxytol-based VSI is feasible using standard MRI techniques in a multicenter study of patients with lesions outside of the brain. Ferumoxytol accumulation in the liver does not preclude measurement of VSI parameters in liver metastases. Magn Reson Med 77:814-825, 2017. © 2016 International Society for Magnetic Resonance in Medicine.
(© 2016 International Society for Magnetic Resonance in Medicine.)
Databáze: MEDLINE
Externí odkaz: